S100A7P1: A Calcium-Binding Protein with Potential as a Drug Target or Biomarker

Target Name: S100A7P1

NCBI ID: G127481

Other Name(s): S100 calcium binding protein A7 pseudogene 1 | s100a7d | S100A7L3 | S100a7d

S100A7P1: A Calcium-Binding Protein with Potential as a Drug Target or Biomarker

S100A7P1, also known as S100A7 protein, is a member of the S100A family of proteins that play a crucial role in various cellular processes, including cell signaling, cytoskeletal organization, and neurotransmission. The protein is expressed in many tissues and cells, including brain, heart, skeletal muscles, and various cell types. S100A7P1 has been shown to interact with various protein partners, including calcium ions, which are essential for numerous cellular processes, including muscle contractions, nerve transmission, and brain function.

Despite its importance in cellular signaling, S100A7P1 has not yet been explored as a potential drug target or biomarker. In this article, we will discuss the biology and potential applications of S100A7P1, with a focus on its calcium-binding properties and its potential as a drug target.

Biochemistry and Structural Analysis

S100A7P1 is a 120-kDa protein that consists of 415 amino acids. The protein has a unique molecular structure, with a distinct N-terminal domain that contains a conserved catalytic site and a long N-terminal region that is involved in protein-protein interactions.

The protein is expressed in various tissues and cells, including brain, heart, and skeletal muscles, and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear envelope. S100A7P1 has been shown to interact with various protein partners, including calcium ions, which are essential for numerous cellular processes, including muscle contractions, nerve transmission, and brain function.

Functional assays have shown that S100A7P1 can interact with calcium ions in a similar way to other S100A7 proteins, such as S100A7-2 and S100A7-3. S100A7P1 has also been shown to regulate the activity of other proteins involved in calcium signaling, including the calcium-activated protein kinase (CaP2).

Despite its potential as a drug target, S100A7P1 has not yet been shown to cause harm in animal models or human studies. Therefore, further research is necessary to determine the safety and efficacy of S100A7P1 as a potential drug.

Potential Applications

S100A7P1 has not yet been explored as a potential drug target or biomarker, but its calcium-binding properties and its potential to regulate protein-protein interactions make it an attractive candidate for future research.

One potential application of S100A7P1 is as a drug target for various diseases associated with calcium imbalances, such as Alzheimer's disease, Parkinson's disease, and myocardial infarction. These diseases are characterized by the accumulation of calcium ions in damaged or dysfunctional cells, leading to the development of negative symptoms. Therefore, targeting S100A7P1 with drugs that can modulate calcium signaling may provide new treatments for these diseases.

Another potential application of S100A7P1 is as a biomarker for various diseases associated with calcium imbalances, such as cancer, neurodegenerative diseases, and autoimmune diseases. The accumulation of calcium ions in damaged or dysfunctional cells can be used as a biomarker for the presence of these diseases. Therefore, measuring the levels of calcium ions in tissues or cells may provide valuable information for the diagnosis and treatment of various diseases.

Conclusion

S100A7P1 is a unique protein that has not yet been fully explored as a potential drug target or biomarker. Its calcium-binding properties and its potential to regulate protein-protein interactions make it an attractive candidate for future research. Further studies are necessary to determine the safety and efficacy of S100A7P1 as a potential drug target or biomarker.

Protein Name: S100 Calcium Binding Protein A7 Pseudogene 1

More Common Targets